A MODIFIED GAMMA INTERFERON, DNA SEQUENCES ENCODING IT AND PROCESSES FOR PRODUCING IT

Abstract: A amino- DELTA 3-gamma interferon, DNA sequences encoding it, and methods of producing it. This amino- DELTA -3-gamma interferon is soluble, easily purifiable, highly stable and has at least a substantially similar level of biological activity as mature IFN- gamma .

Description: A MODIFIED GAMMA INTERFERON, DNA SEQUENCES ENCODING IT AND PROCESSES FOR PRODUCING IT TECHNICAL FIELD OF THE INVENTION This invention relates to a modified gamma interferon, to DNA sequences that code for it, and to processes for making it. More particularly, the invention relates to ah amino-Δ3-gamma interferon which is more soluble, and accordingly easily puri- fiable, and which is highly stable and retains at least a similar level of antiviral and antiprolifera- tive biological activity as full length mature human gamma interferon. This invention also relates to the DNA sequence coding for the amino-Δ3-gamma inter- feron, and to processes for expressing that DNA sequence to produce the amino-Δ3-gamma interferon. In addition, the invention relates to compositions and methods for using this amino-Δ3-gamma interferon in antiviral, antitumor, anticancer or immunomodula- tion applications and methods. Finally, the invention relates to methods and DNA sequences for improving the expression levels of DNA sequences encoding selected proteins and polypeptides, including but not limited to gamma interferon. BACKGROUND ART In this application we will use the inter¬ feron nomenclature announced in Nature, 286, p. 110 (July 10, 1980). "IFN" will designate interferon, "IFN-α" will designate leukocyte interferon, "IFN-β" will designate fibroblast interferon, and "IFN-γ" will designate immune or gamma interferon. The amino- Δ3-gamma interferon of this invention which has three amino acids removed from its amino terminal end will be designated amino-Δ3-IFN-γ. We will also use the conventional three-letter symbols for amino acids as defined in A. Lehninger, Biochemistry, pp. 73-76 (2d ed. 1975). IFN is a cellular protein displaying anti- viral activity against a broad range of viruses through induction of cellular RNA and protein syn¬ thesis directed against virus replication. For example, human IFN has been used to combat; the viral activity of the following: respiratory infections [Texas Reports on Biology and Medicine, Vol. 35, pp. 486-96 (1977) (hereinafter referred to as Texas Reports)] ; herpes simplex keratitis [Texas Reports, pp. 497-500; R. Sundmacher, "Exogenous Interferon In Eye Diseases", International Virology IV, The Hague, Abstract nr. w2/ll, p. 99 (1978)]; acute hemorrhagic conjunctivitis [Texas Reports, pp. 501-10]; adenovirus keratoconjunctivitis [A. Romano et al., ISM MemoI-A8131 (October, 1979)]; varicella-zoster [Texas Reports, pp. 511-15]; cytomegalovirus infection [Texas Reports, pp. 523-27]; and hepatitis B [Texas Reports, pp. 516-22]. See also W. E. Stewart, II, The Inter¬ feron System, pp. 307-21, Springer-Verlag (2 ed. ) (1981) (hereinafter referred to as The Interferon System). IFN has other effects in addition to its antiviral action. For example, it antagonizes the effect of colony stimulating factor, inhibits the growth of hemopoietic colony-forming cells and inter¬ feres with the normal differentiation of granulocyte and macrophage precursors [Texas Reports, pp. 343-49]. It also inhibits erythroid differentiation in DMSO- treated Friend leukemia cells [Texas Reports, pp. 420-28]. IFN may also play a role in the regulation of the immune response. For example, depending upon the dose and time of application in relation to anti- gen, IFN can be both immunopotentiating and immuno- suppressive in vivo and in vitro [Texas Reports, pp. 357-69], In addition, IFN is also known to enhance the activity of killer lymphocytes and anti¬ body-dependent cell-mediated cytotoxicity [R. R. Herberman et al., "Augmentation By Interferon Of Human Natural And Antibody-Dependent Cell-Mediated Cytotoxicity", Nature, 227, pp. 221-23 (1979); P. Beverley and D. Knight, "Killing Comes Naturally", Nature, 278, pp. 119-20 (1979); Texas Reports, • pp. 375-80; J. R. Huddlestone et al., "Induction And Kinetics Of Natural Killer Cells In Humans Following Interferon Therapy", Nature, 282, pp. 417-19 (1979); S. Einhorn et al. , "Interferon And Spontaneous Cyto¬ toxicity In Man. II. Studies In Patients Receiving Exogenous Leukocyte Interferon", Acta Med. Scand. , 204, pp. 478-83 (1978)] . Killer lymphocytes and antibody-dependent cell-mediated cytotoxicity may be directly or in¬ directly involved in the immunological attack on tumor cells. Therefore, in addition to its use as an antiviral agent, IFN has potential application in antitumor and anticancer therapy and in immunomodu- lation agents and methods [The Interferon System, pp. 319-21, 250-56]. It is now known that IFNs affect the growth of many classes of tumors in many animals [The Interferon System, pp. 292-304]. Interferons, like other antitumor agents, seem most effective when directed against small tumors. The antitumor effects of animal IFN are dependent on dosage and time, but have been demonstrated at con- centrations below toxic levels. Accordingly, numerous investigations and clinical trials have been and continue to be conducted into the antitumor and anti- cancer properties of human IFNs. These include treat¬ ment of several malignant diseases such as osteosar- coma, acute myeloid leukemia, multiple myeloma and Hodgkin's disease [Texas Reports, pp. 429-35]. Although the results of these clinical tests are encouraging, the antitumor, anticancer and immunomodu- lation applications of human IFNs have been severely hampered by lack of an adequate supply of purified IFN. Interferon therapy against viruses and tumors or cancers has been conducted at varying dosage regimes and under several modes of administration [The Interferon System, pp. 306-22]. For example, interferon has been effectively administered orally, by inoculation — intravenous, intramuscular, intra- nasal, intradermal and subcutaneous — and in the form of eye drops, ointments and sprays. It is usually administered one to three times daily in dosages of 10 4 to 10 8 units. The extent of the therapy and the dosage regime depends on the patient and the condition being treated. For example, virus infections are usually treated by daily or twice daily doses over several— - days to two weeks and tumors and cancers are usually treated by daily or multiple daily doses over several months or years. The most effective therapy for a given patient must, of course, be determined by the attending physician, who will consider such well known factors as the course of the disease, previous therapy, and the patient's response to interferon in selecting a mode of administration and a dosage regime. Interferons have been classified into two groups: Type I and Type II IFNs. Type I IFNs are the "classical" acid stable IFNs induced by viruses or synthetic polynucleotides and generally consist of two species: IFN-αs and IFN-β. Type II IFN con¬ sists of only one species designated as IFN-γ. IFN-γ is also referred to in the art as immune or gamma interferon. IFN-γ is a glycoprotein induced in lympho- cytes by specific antigen or various mitogens and is antigenically distinct from IFN-α and IFN-β [A. Mizrahi et al., "Glycosylation Of Interferon", J. Biol. Chem., 253, pp. 7612-15 (1978); The Interferon System, pp. 107-08; P. Gray et al., "Expression Of Human Immune Interferon cDNA In E. coli And Monkey Cells", Nature, 295, 503-08 (1982); M. P. Langford et al., "Large-Scale Production And Physicochemical Characteri¬ zation Of Human . Immune Interferon", Infection And Immunity, 26, pp. 36-41 (1979)]. The protein has been reported to have a molecular weight of 40,000- 46,000 daltons, with the possibility that its glyco- sylated form has a molecular weight of 65,000-70,000 daltons. The absence of glycosylation, however, does not substantially affect the biological activity of the protein. Moreover, laboratory tests of both rDNA glycosylated and rDNA non-glycosylated IFN-γ have indicated that the non-glycosylated IFN-γ may be slightly less toxic and slightly more active as an anticancer agent that glycosylated IFN-γ. However, non-glycosylated IFN-γ may be slightly less active as an antiviral agent. In addition to being acid labile (at pH2), IFN-γ has been reported to be inactivated after 1 hour at 56°C. See also M. deLey et al., "Interferon Induced In Human Leukocytes By Mitogens: Production, Partial Purification And Characterization", Eur. J. Immunol. , 10, pp. 877-83 (1980); Y. K. Yip et al., "Partial Purification And Characterization Of Human γ (Immune) Interferon", Proc. Natl. Acad. Sci. USA, 78, pp. 1601-05 (1981). It has been reported that IFN-γ recognizes a different cell receptor than IFN-α or IFNr-β [A. A. Branca et al., "Evidence That Types I And II Interferons Have Different Receptors", Nature., 294, pp. 768-70 (1981)]. Moreover, IFN-γ has been demonstrated in various laboratory studies to have potency against certain viruses, such as herpes genitalis. In addition to its antiviral activity, IFN-γ displays antitumor or anticancer activity. Various studies indicate that IFN-γ works both directly and indirectly to inhibit the growth of, or to kill, certain tumor cells. Moreover, as compared to IFN-α and IFN-β, IFN-γ's antitumor activity, at least in mice, results in tumor regression. In addi¬ tion, its activation of natural killer cells does not reach a plateau, as observed for IFN-α and IFN-β. IFN-γ is also less inhibited by circulating levels of gangliosides than are IFN-α and IFN-β [H. Ankel et al., "Mouse Fibroblast (Type I) And Immune (Type II) Interferons: Pronounced Differences In Affinity For Gangliosides And In Antiviral And Anti- growth Effects On Mouse Leukemia L-1210R Cells", Proc. Natl. Acad. Sci. USA, 77, pp. 2528-32 (1980)]. Therefore, cells or tumors, particularly solid tumors, e.g., lung, breast and colon-rectum cancers, that display a poor response to IFN-α or IFN-β may be effectively treated with IFN-γ [e.g., Crane et al., J. Natl. Cancer Institute, 61, p. 891 (1978); Barn et al., Abstract N.Y. Acad. Sci., No. 11 (October 23-26, 1979); Blalock et al., Cellular Immunology, 49, pp. 390-94 (1980); B. Y. Rubin et al., "Differential Efficacies Of Human Type I And Type II Interferons As Antiviral And Antiproliferative Agents", Proc. Natl. Acad. Sci. USA, 77, pp. 5928-32 (1980)]. Another use of IFN-γ may be as an immuno- regulatory agent. The antiproliferative effect of IFN-γ on transformed cells has been reported to be 10 to 100 times greater than that of IFN-α or IFN-β [P. W. Gray et al., supra] . The DNA sequence coding for human IFN-γ has been cloned and utilized to transform various hosts which then produce IFN-γ [e.g., W. Fiers et al., "The Human Fibroblast And Human Immune Inter¬ feron Genes And Their Expression In Homologous And Heterologous Cells", Phil. Trans. R. Soc. Lond. , B 299, pp. 29-38 (1982); P. W. Gray et al., "Expres- sion Of Human Immune Interferon cDNA in E.coli And Monkey Cells", Nature, 295, pp. 503-08 (1982)]. Various expression control sequence - IFN-γ coding sequence constructions now exist that enable IFN-γ to be produced in appropriately transformed hosts at a high level (≥ 10% of all protein). Such rDNA pro¬ duction of IFN-γ was expected to solve the previous acute shortage of the protein for clinical studies in antiviral, anticancer and immunomodulation methods and agents. However, it has not. Instead, as the transformed cell accumulates large amounts of the foreign IFN-γ protein, the IFN-γ molecules interact with each other to form highly insoluble aggregates not typically found in the normal cell. The cell then may react to this accumulation of protein by forming inclusion bodies into which the foreign protein aggregates are packaged. As a result of this insolubility and cellular packaging, the IFN-γ-containing aggregates may be isolated from the cell. However, after extraction and resuspension in buffer, it has been very difficult to purify the IFN-γ from the bacterial and other cellular extracts of the variety of hosts in which it has been produced. These purification problems have, therefore, disadvan- taged IFN-γ from becoming available in the amounts needed for use in antiviral, anticancer and immunomod¬ ulation methods and compositions. DISCLOSURE OF THE INVENTION The present invention solves the problems referred to above by providing a more soluble, and accordingly easily purifiable, amino-Δ3-IFN-γ in which three amino acid residues have been deleted from the amino terminal end of the IFN-γ as compared to full length IFN-γ. This deletion does not substan¬ tially change the biological activity of the protein. Yet, it provides an IFN-γ-like protein that is highly stable, more soluble, and therefore more easily puri- fi ' able, than previously made recombinant IFN-γ. The amino-Δ3-IFN-γ of this invention may be used in antiviral, antiproliferative or immunomodu- lative compositions, such as those comprising a pharmaceutically effective amount of the protein, or in antiviral, antiproliferative or immunomodulative methods characterized by the step of treating a cell in a pharmaceutically acceptable manner with a pharma¬ ceutically effective amount of such compositions. This invention also includes the DNA sequences coding for the amino-Δ3-IFN-γ and the methods for using those sequences to produce the amino-Δ3-IFN-γ. More preferably, the DNA sequences of this invention are additionally modified by a deletion of nucleotides in the non-coding region of the IFN-γ gene but maintaining at least the poly G tail at the carboxy terminal end of the non-coding region. This deletion further enhances the expression of the gene within the various transformed hosts and results in increased yields of amino-Δ3-IFN-γ. It may also be used alone to enhance the expression levels of other IFN-γ-like polypeptides. Furthermore, such a 3* non-coding deletion in the non-coding region of any DNA sequence coding for a selected protein or polypeptide and carrying a 3 ' poly G tail enhances the expression levels of that DNA sequence in the transformed host cell and improves the levels of selected protein production in that cell. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a schematic outline of one embodiment of a process of this invention for pre¬ paring a recombinant DNA molecule containing a nucleotide deletion in the non-coding region of the cloned IFN-γ gene. Figure 2 is a schematic outline of one embodiment of a process of this invention for pre¬ paring a recombinant DNA molecule containing the nucleotide deletion referred to above and the DNA sequence coding for amino-Δ3-IFN-γ. Figure 3 is a schematic depiction of relevant portions of plasmid per ori γ. Figure 4 is a depiction of a synthetic nucleotide sequence and its use in producing the nine nucleotide deletion in the coding sequence of IFN-γ to produce a DNA sequence encoding amino-Δ3- IFN-γ. Figure 5 is a depiction of the DNA sequence of the IFN-γ-containing insert of a recombinant DNA molecule useful as a starting material in the methods of this invention. BEST MODE OF CARRYING OUT THE INVENTION In order that the invention herein described may be more fully understood, the following detailed description is set forth. In the description, the following terms are employed: DNA Sequence — A linear array of nucleo- tides connected one to the other by phosphodiester bonds between the 3' and 5' carbons of adjacent pentoses. Polypeptide — A linear array of amino acids connected one to the other by peptide bonds between the α-amino and carboxy groups of adjacent amino acids. IFN-γ-Like Polypeptide — A polypeptide displaying substantially the same biological and immunological activity of mature IFN-γ. Expression — A combination of transcrip¬ tion and translation by which a DNA sequence encoding a particular polypeptide produces the polypeptide in a host containing the DNA sequence. Expression Control Sequence — A sequence of nucleotides that controls and regulates expression of DNA sequences when operatively linked to those sequences. Expression control sequences include, for example, the lac system, the trp system, the major operator and promoter regions of phage λ, the control region of fd coat protein, the TAC and TRC systems, and other sequences known to control the expression of DNA sequences of prokaryotic or euka- ryotic cells and their viruses or combinations of those sequences. Cloning Vehicle — A plas id, phage DNA or other DNA sequence which is able to replicate in a host cell, characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production of coat proteins or loss of promoter or binding sites, and which contains a marker suitable for use in the identi¬ fication of transformed cells, e.g., tetracycline resistance or ampicillin resistance. A cloning vehicle is also called a vector. Cloning — A process for obtaining a popu¬ lation of organisms or DNA sequences derived from one such organism or sequence by asexual reproduction. Recombinant DNA Molecule or Hybrid DNA — A molecule consisting of segments of DNA from differ¬ ent genomes which have been joined end to end. This invention provides a stable, biolog- ically active amino-Δ3-IFN-γ, which lacks at its amino terminal end the three amino acid sequence of cysteine-tyrosine-cysteine of mature IFN-γ. This modified IFN-γ, referred to as amino-Δ3-IFN-γ, also displays increased solubility as compared to full length recombinant IFN-γ. It is, therefore, more easily purifiable from cellular extracts than full length recombinant IFN-γ. While not wishing to be bound by theory, applicants believe that the improved solubility of their amino-Δ3-IFN-γ is due to the elimination of the cysteine residues- at the amino terminal end. Cysteines have sulfhydryl side chains which tend to form intermolecular disulfide linkages between indivi¬ dual IFN-γ molecules. Accordingly, these linkages result in highly insoluble protein aggregates within the cell. Such insoluble aggregates complicate puri¬ fication procedures. Thus, the elimination of the cysteine residues from the amino terminal end of IFN-γ prevents these sulfhydryl interactions and pro- vides a more soluble and easily purifiable amino-Δ3- IFN-γ. Production of the amino-Δ3-IFN-γ of this invention begins with the preparation of a DNA sequence coding for that modified interferon. This DNA sequence has a deletion of nine nucleotides at the amino terminal end of the DNA sequence encoding ature IFN-γ. Accordingly, on expression, a protein is produced having the first three amino acids, cysteine-tyrosine-cysteine, deleted from mature IFN-γ. More preferably, an additional number of nucleotides of the 3 1 non-coding (non-translated) region of the IFN-γ gene are also deleted in the DNA sequences of this invention. This latter, and more preferred, construction results in a higher degree of expression of the araino-Δ3-IFN-γ coding sequence in host cells transformed with these sequences. In addition, such a deletion in the 3' non-coding region of any DNA sequence coding for a selected protein or polypeptide and carrying a 3 ! poly G tail results in a higher degree of expression of that protein or polypeptide in transformed host cells. Accordingly, the use of such deletions are part of this invention. Any of a large number of expression vectors, expression control sequences and hosts may be used in combination with the DNA sequences of this inven- tion to produce the desired amino-Δ3-IFN-γ. For example, useful expression vectors may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences, such as various known derivatives of SV40 and known bacterial plasmids, e.g., plasmids from E.coli including col El, pCRl, pBR322, pMB9 and their derivatives, wider host range plasmids, e.g., RP4, phage DNAs, e.g., the numerous derivatives of phage λ, e.g., NM 989, and other DNA phages, e.g., M13 and Filamentous single-stranded DNA phages and vectors derived from combinations of plasmids and phage DNAs such as plasmids which have been modified to employ phage DNA or other expression control sequences or yeast plasmids such as the 2μ plasmid or derivatives thereof. Useful cloning or expression hosts may include bacterial hosts such as E.coli KB 101, E.coli X1776, E.coli X2282, E.coli MRC1 and strains of Pseudomonas, Bacillus subtilis, Bacillus stearothermophilus and other bacilli, yeast and other fungi, animal or plant hosts such as animal (including human) or plant cells in culture or other hosts. It should be understood that the selection of a particu- lar host will determine whether or not the amino-Δ3- IFN-γ is glycosylated or non-glycosylated. For example, if made in mammalian cells, e.g., CHO cells, the amino-Δ3-IFN-γ will be glycosylated, while if made in E.coli, it will be non-glycosylated. Both forms of amino-Δ3-IFN-γ are included within this invention. Various expression control sequences may be employed. These include, for example, the oper¬ ator, promoter and ribosome binding and interaction sequences (including sequences such as the Shine- Dalgarno sequences) of the lactose operon of E.coli ("the lac system"), the corresponding sequences of the tryptophan synthetase system of E.coli ("the trp system"), the major operator and promoter regions of phage λ (0-.P-. and 0„P R ), a control region of Filamentous single-stranded DNA phages, or other sequences which control the expression of genes of prokaryotic or eukaryotic cells and their viruses or combinations thereof. Of course, not all vector-expression control sequence-host combinations may be equally efficient. The particular selection of a specific combination may be made by those of skill in the art after due consideration of the principles set forth without departing from the scope of this invention. It should also be understood that because neither the coding sequence for mature IFN-γ nor the coding sequence for amino-Δ3-IFN-γ begin with an ATG start codon, this translational start signal must be inserted in front of the coding sequence before expression. Such constructions of an ATG-coding sequence combination may be done by those of skill in the art without departing from the scope of this invention. These constructions enable the production in appropriate transformed hosts of f-met-IFN-γ or f-met-amino-Δ3-IFN-γ. However, heterogeneity due to the presence or absence of the amino terminal Met cannot be excluded because some hosts, e.g., E.coli, are known to cleave to some extent amino terminal methionines. In order that this invention and the methods of using it may be more fully understood, the follow¬ ing example is provided. This example is for illus¬ trative purposes only. Other means and methods may be employed to construct, to produce and to use the amino-Δ3-IFN-γ of this invention without departing from the scope hereof. EXAMPLE Referring to Figures 1 and 2, we have shown therein a schematic outline of one embodiment of a process for preparing the more preferred DNA sequence of this invention. This sequence encodes amino-Δ3- IFN-γ and also carries a 422-nucleotide deletion in the 3' non-coding region of IFN-γ. According to this embodiment, we first deleted 422 nucleotides from the 3' non-coding region of the IFN-γ gene by nuclease digestion. We then deleted the nine nucleo¬ tides after " the ATG start codon in the 5' coding region (amino terminal end) of the IFN-γ gene by site specific mutagenesis. The starting material used in the embodiment of this invention described here is recombinant DNA molecule per ori γ (Figure 1(a)) which contains the DNA sequence encoding mature IFN-γ, operatively linked to a trp-derived expression control sequence (see, e.g.. Figures 3 and 5). This molecule also has a translation start signal (ATG) attached to the coding sequence (TGT) of the first amino acid of mature IFN-γ and contains a Clal restriction site between the Shine-Dalgarno sequence of the trp expression control sequence and the start codon (Figures 3 and 5). As shown more particularly in Figures 3 and 5, this molecule also contains a portion of the 3' non- coding (non-translated) region of the IFN-γ gene with a BamHI restriction site marking the carboxyl end of this non-coding region. The non-coding region also contains Xhol and Rsal restriction sites within its sequence. The remainder of the molecule (from the BamHI site to the trp sequence) is comprised of the sequences of plasmid pBR322 and contains a PstI restriction site. Although we used this recombinant • DNA molecule as our starting material in this illus- trative example of our invention, it should be under¬ stood that any other source of the IFN-γ coding or non-coding region could have been equally well employed to produce our amino-Δ3-IFN-γ. As depicted in Step (a) of Figure 1, we first restricted per ori γ with Rsal and inserted HindiII linkers to construct a HindiII restriction site in the 3' non-coding region of the IFN-γ gene. We then restricted the resulting plasmid with HindiII and separated the linearized DNA into two aliquots (Step (b). Figure 1). As depicted in Step (c) of Figure 1, we treated one aliquot of the above HindiII cleaved DNA with SI micrococcal nuclease to blunt end the residues of the Hindi11 restriction cut. We purified this DNA on an agarose gel, restricted it with PstI, and purified the larger resulting fragment (containing the BamHI site) on an agarose gel (Step (d), Figure 1). We digested the other aliquot of the HindiII cleaved DNA with Bal 31 nuclease, an enzyme that digests double-stranded DNA, under conditions that removed 422 nucleotides from each end of the linear DNA (Step (c), Figure 1). After purification of the digested DNA on an agarose gel, we restricted the DNA with PstI and purified the smaller resulting fragment (containing the trp control sequence, the coding region of the IFN-γ gene and a portion of the beginning of the non-coding region of the IFN-γ gene) (Step (d), Figure 1). The non-coding region of the IFN-γ gene on the selected fragment had been digested from the HindiII site toward the coding region of the IFN-γ gene, resulting in a 422-nucleotide deletion in that region. This deletion is depicted by the brackets in Figure 5. The two DNA fragments produced above were then ligated to form a recircularized DNA character¬ ized by a 422-nucleotide deletion in the 3' non-coding region of the IFN-γ gene (Step (e), Figure 1). This deletion results in a higher level of expression of the IFN-γ gene in cells transformed with the molecule, i.e., approximately 20-30% of the total cellular protein. This deletion is useful in the expression of any IFN-γ coding sequence. Accordingly, it need not be combined as " below with the coding sequence for amino-Δ3-IFN-γ. Instead, it may be advantageously employed in the production of other IFN-γs and IFN-γ- like polypeptides. By use of Xbal linkers and allowing longer Bal 31 nuclease digestion as described above, we also constructed a DNA characterized by a 484-nucleotide deletion in the 3 ! non-coding region of the IFN-γ gene. This deletion provides an equal or somewhat greater yield of IFN-γ as is obtained with the 422- nucleotide deletion. Utilizing the methods of the invention, therefore, a deletion of any nucleotide length in the 3' non-coding region of the IFN-γ gene may be constructed to provide increased yields of IFN-γ. After incorporation of the above-described deletion into the IFN-γ gene, we then introduced a 9-nucleotide deletion in the 5' coding region of the IFN-γ gene to produce a coding sequence for amino-Δ3- IFN-γ. It should be understood that while we first manipulated our starting recombinant DNA molecule, per ori γ, to introduce the 422-nucleotide non-coding deletion, we could as well have introduced the 9-nucleotide deletion in the amino terminal end first or even not combined that deletion with the 422- nucleotide non-coding deletion. However, preferably, our expression vehicle carries both deletions because high levels of expression are obtained. As shown in Figure 2, we treated the recir- cularized molecule in two ways. We restricted one aliquot of the DNA with Clal and BamHI, using the conditions recommended by the suppliers of those endonuclease restriction enzymes, and isolated and purified the larger Clal-BamHI fragment on an agarose gel (Step (a), Figure 2). The fragment contains a part of the trp expression control sequence, a PstI restriction site and a part of the 3' non-coding region of the IFN-γ gene (Figure 2b). We then dena¬ tured this fragment (which is double-stranded) in 0.1N NaOH at room temperature for 10 min to produce single-stranded Clal-BamHI DNA fragments (Step (b), Figure 2). We restricted the second aliquot of our recircularized molecule with PstI to linearize it and purified the linear DNA on an agarose gel (Step (a), Figure 2). We then denatured this linear double-stranded DNA in 0.1N NaOH at room temperature for 10 min to produce single-stranded DNAs (Step (b), Figure 2) . We next mixed the single-stranded DNA frag¬ ments produced by the two above-described restrictions at 60°C in Tris-HCl(pH 8)-EDTA-NaCl ("TEN") hybridiza- tion buffer for 2-3 h (Step (c), Figure 2). This reannealed the DNA fragments to form a renatured double-stranded plasmid with a gap in one strand between the Clal and BamHI restriction sites (Fig- ure 2). We then purified the renatured DNA by pre¬ cipitation in ethanol and redissolved the purified DNA in ligase/polymerase buffer. We next prepared a synthetic oligonucleo- tide primer, having the sequence CGATACTATGCAGGACCC. As depicted in Figure 4, this primer is complementary to the DNA sequence of molecule per ori γ in the region of the trp control sequence and the coding region of the IFN-γ gene. However, the primer carries a deletion of nine nucleotides as compared to that DNA sequence of molecule per ori γ. The deleted sequence, TGTTACTGC, corresponds to the coding sequence of the first three amino terminal amino acids cysteine-tyrosine-cysteine of IFN-γ. Accord¬ ingly, the primer after hybridization to one strand of per ori γ enables the synthesis of a DNA sequence lacking those 9-nucleotides. We hybridized the above-described primer to the single-standed DNA portion of our renatured DNA, described above (Step (d), Figure 2). We affected this hybridization in ligase/polymerase buffer at 17°C to ensure that the 9-nucleotide dele¬ tion would.not prevent hybridization. We then filled in the single-stranded DNA gap using the four deoxy- ribonucleotide triphosphates, DNA polymerase I (Klenow fragment) and ligase (Step (e). Figure 2). This procedure results in the production of a double- stranded DNA having on one strand the complete coding sequence of IFN-γ and having on the other strand a DNA sequence lacking the nine nucleotides which code for the first three amino terminal amino acids of IFN-γ (Figure 4) . We then transformed E.coli K12 cells with our filled-in, double-stranded DNA and selected those hosts that had been transformed with the DNA sequence carrying the nine nucleotide deletion on one strand (Step (f), Figure 2). For selection, we used our synthetic primer sequence as a probe in a Grunstein- Hogness hybridization screening at 42°C [H. Grunstein and D. S. Hogness, "Colony Hybridization: A Method For The Isolation Of Cloned DNAs That Contain A Specific Gene", Proc. Natl. Acad. Sci. USA, 72, pp. 3961-65 (1975)]. During hybridization selection we distinguished between weak signals (where a mis¬ match occurred) and strong signals (where there was no mismatch). We took the selected hosts (strong signal, no mismatch with probe) that contained a DNA sequence carrying on one strand the desired 9-nucleotide dele¬ tion, grew them up in rich medium, lyzed them, and observed two protein bands, one corresponding to the full length IFN-γ and the other corresponding to the amino-Δ3-IFN-γ. The reason we observed two bands is that the cultured cells, having undergone replication, now contain two types of molecules. (Step (f), Fig¬ ure 2). One is formed by replication of the DNA strand that contains the full length IFN-γ coding sequence and the other is formed by replication of the DNA strand that has the 9-nucleotide deletion following the start codon of the IFN-γ gene. Accord¬ ingly, we made minipreps from the positive host cells and separated the two types of plasmids using Grunstein-Hogness hybridization selection with the synthetic probe at 42°C as before, selecting the strongly-positive plasmids (Step (g), Figure 2). We then transformed E.coli K12 cells with these selected plasmids, now containing only DNA sequences having the nine nucleotide deletion at the 5' end of the IFN-γ coding sequence (see the nucleo- tide sequence within the box in Figure 5). Af er culturing these hosts, we observed a protein band for the amino-Δ3-IFN-γ. No band was observed for full length IFN-γ. We have designated this plasmid carrying DNA sequences with a nine nucleotide dele¬ tion at the 5' end of the IFN-γ gene and a 422- nucleotide deletion in the 3' non-coding region: ptrp-amino-Δ3-IFN-γ-Δ422. We have designated the host transformed with this plasmid which produces the amino Δ3-IFN-γ: E.coli K12 (ptrp-amino-Δ3-IFN- γ-Δ422). The amino-Δ3-IFN-γ prepared above was then compared with full length IFN-γ, prepared from E.coli hosts transformed with per ori γ, in terms of its antiviral and antiproliferative activities. This comparison demonstrated that the amino-Δ3-IFN-γ had at least similar antiviral and antiproliferative activities to recombinant IFN-γ from per ori γ. Moreover, the amino-Δ3-IFN-γ was highly soluble and accordingly easy to purify. It was also very stable in solution. It should, of course, be understood that while we have described one method for producing amino-Δ3-IFN-γ, a variety of other methods may also be employed to prepare this modified IFN-γ. For example, at the DNA level, other methods may be used to produce the coding sequence of amino-Δ3-IFN-γ. These include synthetic methods and other mutagenesis and deletion methods. At the protein level, a variety of techniques also exist to produce amino-Δ3-IFN-γ. It should also be understood that while the above example is directed to an amino-Δ3-IFN-γ encoded by a DNA sequence also having an additional 422- or 484-nucleotide deletion in the non-coding region of the IFN-γ gene, this invention is not so limited. Rather, it includes DNA sequences containing a nucleotide deletion in the 3' non-coding region which may be of varying length, the deletion prefer¬ ably starting at the Rsal endonuclease recognition site and continuing toward the coding region of the IFN-γ gene. In addition, the invention includes DNA sequences coding for amino-Δ3-IFN-γ which contain only the nine nucleotide deletion at the amino termi¬ nal end of the coding region of the gene. In such an instance, only the schematic outline of Figure 2, for example, would be used and Xhol restriction instead of BamHI restriction would be preferred. Furthermore, the present invention also extends to DNA sequences coding for any protein or polypeptide and carrying a 3* poly G tail, the DNA sequences containing a nucleotide deletion in the 3 ' non-coding region of the gene but maintaining at least the poly G tail at the carboxy terminal end of the non-coding region. This deletion enhances the level of expression of the DNA sequences in host cells transformed with those DNA sequences and results in increased yields of the protein or polypeptide. Microorganisms, recombinant DNA molecules, and DNA sequences prepared by the processes of this invention are exemplified by cultures deposited in the culture collection Deutsche Sammlung von Mikro- organismen in Gottingen, West Germany on March 12, 1984: E.coli K12 (ptrp-amino-Δ3-IFN-γ) E.coli K12 (ptrp-amino-Δ3-IFN-γ-Δ422) E.coli K12 (ptrp-amino-Δ3-IFN-γ-Δ484) These cultures were assigned accession numbers DSM 2920, 2921 and 2922, respectively. While we have herein presented a number of embodiments of this invention, it is apparent that our basic construction can be altered to provide other embodiments which utilize the process and compo¬ sition of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than by the specific embodiments which have been presented hereinbefore by way of example.

Claims: We claim: 1. A DNA sequence that codes on expression for amino-Δ3-IFN-γ, wherein the cysteine, tyrosine, cysteine amino acid sequence is deleted from the amino terminal end of mature IFN-γ. 2. The DNA sequence of claim 1, wherein an ATG start codon is attached directly to the codon coding for the fourth amino terminal amino acid of mature IFN-γ. 3. A DNA sequence that on expression codes for an interferon-like polypeptide and which includes the 3' non-coding region of the IFN gene, and a 3' poly G tail, said DNA sequence having a nucleotide deletion of at least a portion of the 3' non-coding region but maintaining the poly G tail at the carboxy terminal end of the non-coding region of the IFN gene. 4. The DNA sequence of claim 3, wherein said DNA sequence has a deletion of 422 nucleotides in the 3' non-coding region of the IFN gene, said deletion starting at the Rsal endonuclease recogni¬ tion site and continuing toward the coding region of the IFN gene. 5. The DNA sequence of claim 3, wherein said DNA sequence has a deletion of 484 nucleotides in the 3 1 non-coding region of the IFN gene, said deletion starting at the Rsal endonuclease recogni¬ tion site .. and continuing toward the coding region of the IFN gene. 6. A DNA sequence that codes on expres¬ sion for amino-Δ3-IFN-γ, wherein the cysteine, tyrosine and cysteine amino acid sequence is deleted from the amino terminal end of mature IFN-γ, and which includes the 3' non-coding region of the IFN-γ gene and a poly G tail, said DNA sequence having a nucleotide deletion of at least a portion of the 3' non-coding region but maintaining the poly G tail at the carboxy terminal end of the non-coding region of the gene. 7. The DNA sequence of claim 6, wherein said DNA sequence has a deletion of 422 nucleotides in the 3' non-coding region of the IFN-γ gene, said deletion starting at the Rsal endonuclease recogni¬ tion site and continuing toward the coding region of the IFN-γ gene. 8. The DNA sequence of claim 6, wherein said DNA sequence has a deletion of 484 nucleotides in the 3' non-coding region of the IFN-γ gene, said deletion starting at the Rsal endonuclease recogni¬ tion site and continuing toward the coding region of the IFN-γ gene. 9. The DNA sequence of claim 6, wherein an ATG start codon is attached directly to the codon coding for the fourth amino terminal amino acid of mature IFN-γ. 10. A recombinant DNA molecule character¬ ized by a DNA sequence selected from the group con¬ sisting of the DNA sequences according to any one of claims 1, 2, 6, 7, 8 and 9, said DNA sequence being operatively linked to an expression control sequence in said recombinant DNA molecule. 11. A recombinant DNA molecule character¬ ized by a DNA sequence according to any one of claims 3, 4 and 5, said DNA sequence being operatively linked to an expression control sequence in said recombinant DNA molecule. 12. A host transformed with at least one recombinant DNA molecule according to claim 10 or 11. 13. A polypeptide selected from the group consisting of amino-Δ3-IFN-γ, f-met-amino-Δ3-IFN-γ and mixtures thereof. 14. The polypeptide of claim 13 selected from the group consisting of glycosylated and non- glycosylated polypeptides. 15. A polypeptide produced by fermentation of a host transformed with a recombinant DNA molecule according to claim 10 or 11. 16. A method for producing an amino-Δ3- IFN-γ comprising the steps of culturing a host trans¬ formed by a- recombinant DNA molecule according to claim 10 and collecting said polypeptide. 17. A method for producing an IFN-γ-like polypeptide comprising the steps of culturing a host transformed by a recombinant DNA molecule according to claim 11 and collecting said polypeptide. 18. An antiviral composition which com¬ prises a pharmaceutically effective amount of at least one polypeptide selected from the group con¬ sisting of a polypeptide according to any one of claims 13-15. 19. An antiproliferative composition which comprises a pharmaceutically effective amount of at least one polypeptide selected from the group con¬ sisting of a polypeptide according to any one of claims 13-15. 20. An immunomodulation composition which comprises a pharmaceutically amount of at least one polypeptide selected from the group consisting of a polypeptide according to any one of claims 13-15. 21. An anticancer composition which com¬ prises a pharmaceutically effective amount of at least one polypeptide selected from the group con¬ sisting of a polypeptide according to any one of claims 13-15. 22. An antiviral, antiproliferative, anti¬ cancer, or immunomodulative method characterized by the step of treating a cell in a pharmaceutically acceptable manner with a pharmaceutically effective amount of a composition comprising at least one poly¬ peptide according to any one of claims 13-15. 23. A method for improving the level of expression of a DNA sequence coding for a selected protein or polypeptide and carrying a 3' poly G tail in a host transformed with said DNA sequence, com¬ prising the steps of deleting at least a portion of the 3' non-coding region of the DNA sequence coding on expression for that protein or polypeptide but maintaining the poly G tail, culturing the host transformed with a recombinant DNA molecule con¬ taining said DNA sequence and collecting said pro- tein or polypeptide. 24. A DNA sequence that codes on expres¬ sion for a protein or polypeptide and which includes the 3' non-coding region of the gene for said protein or polypeptide and a 3' poly G tail, said DNA sequence having a nucleotide deletion of at least a portion of the 3' non-coding region but maintaining the poly G tail at the carboxy terminal end of the non-coding region. 25. A recombinant DNA molecule charac¬ terized by the DNA sequence of claim 24, said DNA sequence being operatively linked to an expression control sequence in said recombinant DNA molecule. 26. A host transformed with at least one recombinant DNA molecule according to claim 25.

Inventors: ALLET BERNARD, ALLET, BERNARD
Applicants: BIOGEN NV, BIOGEN N.V.
Application year: 1985
Main classification: C12N15
IPC codes: A61K38, C07K14, C12N15